USV Private Limited, a leading name in diabetes care, has announced the launch of USEMA, its semaglutide injection, for the management of Type 2 Diabetes Mellitus in India. With diabetes prevalence rising rapidly across the country, particularly among individuals with overweight and obesity, the introduction of USEMA aims to address a critical and growing healthcare need.USEMA is available in two pen formats: a 2 mg pen delivering 0.25 mg and 0.5 mg doses, and a 4 mg pen delivering a 1 mg dose, offering flexibility in treatment based on patient requirements. Manufactured in India under stringent global quality standards, the product demonstrates proven bioequivalence, with similar efficacy, safety, and immunogenicity profiles as the reference innovator.Developed through an integrated manufacturing process—from active pharmaceutical ingredient (API) to finished formulation—USEMA ensures consistency in quality, supported by robust cold-chain management.Beyond treatment, USEMA is supported by a comprehensive patient care program designed to guide individuals through every stage of their diabetes journey. This initiative focuses on improving adherence, outcomes, and long-term health milestones.With over six decades of experience, USV continues to strengthen its commitment to advancing diabetes care in India through innovation and patient-centric solutions.